Investor's Business Daily on MSN

Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Gartner (NYSE:IT) Posts Q3 Sales In Line With Estimates

Research and advisory firm Gartner (NYSE:IT) met Wall Streets revenue expectations in Q3 CY2025, with sales up 2.7% year on year to $1.52 billion. Its non-GAAP profit of $2.76 per share was 13.7% ...